Connect with us

BioPharma

Healthier Choices Management Corp. (OTCMKTS: HCMC) Major Run in the Works as HCMC Prepares Release of Exhibits That Prove the IQOS Device Does Combust

Published

on

Healthier Choices Management Corp. (OTCMKTS: HCMC) is easily among the most exciting stocks in small caps that has emerged in recent months as one of the most talked about and searched for stocks in the OTC with over 400,000 shareholders of record. Currently under heavy accumulation HCMC has been attracting some pretty heavy hitters who see big things in the works here. HCMC broke south of support levels last week in a fake down to $0.0004 before coming back strong over support levels with power signaling to investors the next leg up is upon us with lots of catalysts in play for next week which should be a big one. A break over $0.0065 and its blue skies ahead for HCMC. Investors are looking for a huge lift once HCM is able to provide documents that the IQOS device does combust and the case will move forward. Representing HCMC is Cozen O’Connor ranked among the top 100 law firms in the country and employing more than 775 attorneys in 29 cities across two continents. The firm’s diverse client list includes global Fortune 500 companies, middle-market firms poised for growth, high-profile individuals and HCMC who must have a seriously solid case against PMI with outstanding chances.

On July 23, the District Court for the Northern District of Georgia granted Philip Morris motion to dismiss HCMC’s patent infringement action against them. HCMC has fourteen days to file a motion for leave to file a further amended complaint, which HCMC intends to do by said deadline which is August 5. The entire case boils down to whether PMs IQOS device combusts and if HCM can prove the IQOS device combusts. According to the lawsuit: Claim 1: the first of two independent claims for HCM’s patent, recites several limitations, including that the electronic pipe transmits an electric current from the battery to the heating element…initiating a combustion reaction and 11: Claim 5 the other independent claim recites a method for igniting the pipe that includes initiating by way of the heating element, a combustion reaction. To ensure that the pleading nevertheless meets twombly/iqbal plausibility standard, the courts require plaintiff’s to “do more than assert that the product infringes the claim; it must show how the defendant plausibly infringes by alleging some facts connecting the allegedly infringing product to the claim elements. This is usually done by exhibits in the form of attachments which HCMC did provide. Exhibit J is PM’s FDA report where the FDA was discussing the marketability of the IQOS device determine whether it combusts or not for health reasons. Judge Timothy C. Batten, points out that because it was attached to the complaint it can now be part of the lawsuit and the battle to dismiss. Judge Batten decided he was not going to decide Summary judgement, the problem is that HCM is arguing that there is combustion but their attachment says there is no combustion. HCMC now has 14 days to provide new documents that show the IQOS device does in fact combust as they have been alleging all along. If HCM can show that the IQOS device does in fact combust than the case will move forward, if not than HCMC lawsuit against PM will be over. At the same time, we have about a month and a half wait for HCMC to respond to PMs petition to the patent office for a review of HCMs patents. HCMC most likely will be able to provide documents that the IQOS device does combust and the case will move forward. 

Healthier Choices Management Corp. (OTCMKTS: HCMC) operates via a number of divisions producing growing revenues. Operating via its subsidiaries, Healthy Choice Markets and Healthy Choice Markets 2, the Company operates both Ada’s Natural Market, a 18,000 sq. ft. full-service grocery store serving the Fort Myers, FL, and three Paradise Health & Nutrition locations in the greater Melbourne, FL area. HCMC operates 8 vape stores across the southern US offering alternatives to traditional cigarettes. Operating regionally, through its Vape Store brands, including The Vape Store, Vapor Max, Vulcan Vape, and The Grab Bag locations, the Company’s Vape Stores provide a large selection of vaping hardware and e-liquids. HCMC is already a revenue powerhouse doing over $1 million per month in sales in 2020; on March 5 HCMC announced financial results for the fourth quarter and fiscal year ended December 31, 2020. In Q4 the Company delivered improvement in adjusted EBITDA for fiscal year 2020. Net sales from continued operations for the year ended December 31, 2020 amounted to $13.9 million, compared to $15.1 million during the same period last year.   

HCMC owns a valuable patent portfolio related to both vape technology and also manufacturing processes and procedures for an imitation nicotine product. HCMC patented Q-Cup™ technology is based on a small, quartz cup called the Q-Cup™, which can be bought already filled by a third party in some regions, or can partially fill themselves with either cannabis or CBD concentrate also purchased from a third party.  The Q-Cup™ can then be inserted into the patented Q-Unit™, which heats the cup from the outside.  The Q-Cup™ and Q-Unit™ technology provides more efficiency and an excellent solution for consumers.  The Q-Cup™ can also be used in other devices as a convenient micro-dosing system. Most recently, HCMC formed a wholly owned subsidiary, HCMC Intellectual Property Holdings, LLC, to hold and market its intellectual property assets. The subsidiary will own all of the patents, trademarks and other intellectual property of HCMC and will be utilized in the company’s attempt to monetize its intellectual property.   

HCMC has an excellent CEO working hard behind the scenes; CEO Jeffrey Holman; a seasoned executive and corporate lawyer also serves as President of Jeffrey E. Holman & Associates, P.A., a South Florida Based law firm. Christopher Santi, the Company’s COO and President is sales executive who served as President of Santi Management Corporation before joining the Company. 

HCMC filed a patent infringement lawsuit in the United States District Court for the Northern District of Georgia against PM (Philip Morris USA, Inc. and Philip Morris Products S.A.) concerning PMs “IQOS®.” Cozen O’Connor is representing HCMC in their lawsuit against Phillip Morris which claims that PM is infringing on HCMC’s patent rights in connection with IQOS®, which is an alternative tobacco product marketed and sold by Phillip Morris. PM has already invested over $3 billion in their smokeless tobacco products and is approaching 14 million users of its IQOS® This is part of PMs ongoing transition from traditional cigarettes to modified risk tobacco products, such as IQOS®. The IQOS® is currently the subject of a number of lawsuits including two other patent infringement proceedings filed by RJ Reynolds Tobacco Company.   

Earlier this year PM filed a petition with the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office seeking to institute inter party review proceedings to invalidate HCMs U.S. Patent No. 10,561,170. HCMC management is currently reviewing Philip Morris’ IPR petitions and will oppose the institution of the IPR proceedings and, if the IPR proceedings are instituted, the Company is fully prepared to vigorously defend the validity of the Patent. 

The law firm representing HCM is Cozen O’Connor, an international law firm employing 775 attorneys in 29 cities across two continents. The Company is ranked among the top 100 law firms in the US and its diverse client list includes global Fortune 500 companies, middle-market firms poised for growth, high-profile individuals and ambitious upstarts like HCMC. The firm has been awarded as the #1 law firm of the year several times. 

https://twitter.com/Jon27642561/status/1420437843546099716

Subscribe to Microcapdaily Right Now for more on HCMC by entering your email below 

HCMC

HCMC

Microcapdaily started to report on HCMC in January 2021 stating at the time: “Healthier Choices Management Corp (OTCMKTS: HCMC) is making a swift move up the charts in recent days trading billions of shares and emerging as a volume leader in small caps. On Wednesday alone HCMC dollar volume topped $20 million USD.”

The Company recently launched its patented quartz Q-Cups® with the health center in Colorado, which The Health Center will pre-fill with their high quality NUHI brand concentrates and make available to consumers in their Colorado dispensaries. The Health center plans to distribute their high quality NUHI concentrate product in HCMC Q-Cup® technology. HCMC also entered into an Exclusive Authorized Filling Agreement for its Q-Cup®technology in Canada with 6PAK Solutions Inc., the sister company and distribution arm of ATG Pharma Inc. ATG Pharma is a leading manufacturer of filling machines in both Canada and the U.S, and manufacturer of the Q-Cup® robotic filling machine. 

On July 20 U.S. Patent Number 11,064,732 entitled Electronic Vaporizer Cartridge with Encased Heat Source was issued to HCMC. This patent covers novel HCMC technology directed at a vaporizer cartridge with internal components encased in a non-reactive material such as quartz, ceramic or the like. This process avoids a potentially toxic reaction between e-liquid, cannabis or CBD oils, or other substances, and the heated metal components of the cartridge. This patent grant expands HCMC’s portfolio of patent assets that promote a healthier way to vape. 

https://twitter.com/RadicalNoncents/status/1420476744268533761

For More on HCMC Subscribe Right Now! 

Healthier Choices Management Corp is easily among the most exciting stocks in small caps that has emerged in recent months as one of the most talked about and searched for stocks in the OTC with over 400,000 shareholders of record. Currently under heavy accumulation HCMC has been attracting some pretty heavy hitters who see big things in the works here. HCMC broke south of support levels last week in a fake down to $0.0004 before coming back strong over support levels with power signaling to investors the next leg up is upon us with lots of catalysts in play for next week which should be a big one. A break over $0.0065 and its blue skies ahead for HCMC. Investors are looking for a huge lift once HCM is able to provide documents that the IQOS device does combust and the case will move forward. Representing HCMC is Cozen O’Connor ranked among the top 100 law firms in the country and employing more than 775 attorneys in 29 cities across two continents. The firm’s diverse client list includes global Fortune 500 companies, middle-market firms poised for growth, high-profile individuals and HCMC who must have a seriously solid case against PMI with outstanding chances. On July 23, the District Court for the Northern District of Georgia granted Philip Morris motion to dismiss HCMC’s patent infringement action against them. HCMC has fourteen days to file a motion for leave to file a further amended complaint, which HCMC intends to do by said deadline which is August 5. The entire case boils down to whether PMs IQOS device combusts and if HCM can prove the IQOS device combusts. According to the lawsuit: Claim 1: the first of two independent claims for HCM’s patent, recites several limitations, including that the electronic pipe transmits an electric current from the battery to the heating element…initiating a combustion reaction and 11: Claim 5 the other independent claim recites a method for igniting the pipe that includes initiating by way of the heating element, a combustion reaction. To ensure that the pleading nevertheless meets twombly/iqbal plausibility standard, the courts require plaintiff’s to “do more than assert that the product infringes the claim; it must show how the defendant plausibly infringes by alleging some facts connecting the allegedly infringing product to the claim elements. This is usually done by exhibits in the form of attachments which HCMC did provide. Exhibit J is PM’s FDA report where the FDA was discussing the marketability of the IQOS device determine whether it combusts or not for health reasons. Judge Timothy C. Batten, points out that because it was attached to the complaint it can now be part of the lawsuit and the battle to dismiss. Judge Batten decided he was not going to decide Summary judgement, the problem is that HCM is arguing that there is combustion but their attachment says there is no combustion. HCMC now has 14 days to provide new documents that show the IQOS device does in fact combust as they have been alleging all along. If HCM can show that the IQOS device does in fact combust than the case will move forward, if not than HCMC lawsuit against PM will be over. At the same time, we have about a month and a half wait for HCMC to respond to PMs petition to the patent office for a review of HCMs patents. HCMC most likely will be able to provide documents that the IQOS device does combust and the case will move forward. We will be updating on HCMC when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with HCMC.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in HCMC either long or short and we have not been compensated for this article.

BioPharma

Organogenesis (NASDAQ: ORGO): Latest Developments and Future Growth Prospects

Published

on

Organogenesis Holdings (NASDAQ: ORGO), a top regenerative medicine company dedicated to advanced wound care, surgical, and sports medicine solutions, gains over 30% during intraday trading and after hours combined after their latest release. According to the release, three Medicare Administrative Contractors (MACs) decided to withdraw certain coverage rules that were meant to start on October 1. These rules related to products for treating diabetic foot ulcers (DFU) and venous leg ulcers (VLU).

More Background:

Organogenesis serves a range of clients, from hospitals and wound care centers to doctors’ offices. The MACs’ initial rules, set on August 9, caused concern. They specified that covered products must be particular types of skin substitutes. Unfortunately, this excluded five products from Organogenesis, impacting their financial outlook.

Fast forward, the MACs pulled back these rules just in time, preventing potential harm to Organogenesis. Even before these rules, the company was facing challenges. In the second quarter, revenue was slightly down compared to the same period last year. Despite this, the company is doing better than the previous year in a six-month comparison.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Gary S. Gillheeney, Sr., the head of Organogenesis, expressed deep gratitude for the MACs and the Centers for Medicare & Medicaid Services (CMS). He praised their thoughtful consideration of stakeholder concerns and putting patients first. This decision will positively affect the lives of many.

He also thanked the stakeholders, including doctors, patient advocacy groups, and various associations. Their unified support played a vital role in challenging these rules, considering the potential harm they could cause patients. Their advocacy shed light on the possible negative health outcomes and treatment disparities, especially for those with higher rates of diabetes and related conditions. Their collective efforts made a significant difference.

We will update you on ORGO when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by Parentingupstream from Pixabay

Continue Reading

BioPharma

Vaccitech (NASDAQ: VACC) Gains Unprecedented Support—What’s Behind It?

Published

on

On September 25, 2023, Vaccitech (NASDAQ: VACC) experienced a jaw-dropping 90% surge in its stock price in just one day of trading. Now, this kind of jump usually happens when a company drops a major announcement or puts out a significant SEC filing. But, surprise, surprise—there was nothing of that sort this time .So naturally we did some digging, explored further online and guess what? Turns out retail traders were also not on a main reason for this rollercoaster ride. Curious to uncover what’s really behind this financial rollercoaster? Before we go any further, let’s get to know Vaccitech a bit better. There’s some pretty important aspects on the company you might like.

 

Background:

Vaccitech operates as a clinical-stage biopharmaceutical company, dedicated to discovering and developing innovative T cell immunotherapies. These therapies are crafted to leverage the immune system’s potency for treating conditions like chronic infectious diseases, cancer, and autoimmune disorders.

What sets Vaccitech apart is their distinctive, multi-platform approach, demonstrating the capacity to generate higher quantities of T cells compared to alternative technologies. This places Vaccitech in a unique position to cater to the needs of substantial, yet underserved patient populations. Their diverse clinical-stage pipeline includes potential treatments for severe diseases with limited available treatments, presenting significant public health risks.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Among their lead product candidates are VTP-300, an immunotherapeutic designed to contribute to a potential functional cure for chronic hepatitis B viral (HBV) infection. Additionally, VTP-200 is a non-invasive, early-stage investigational treatment targeting persistent, high-risk human papillomavirus (HPV). VTP-850 stands out as a novel T cell investigational therapy aimed at prostate cancer, while VTP-1000, a preclinical T cell therapeutic candidate, focuses on reinstating immune tolerance in celiac disease.

Vaccitech possesses well-established expertise in drug development and scientific knowledge within the immunization realm. Notably, they co-developed a COVID-19 vaccine in collaboration with the University of Oxford. As many of you know, their vaccine has been successfully approved and holds an exclusive license worldwide with AstraZeneca.

What happened:

The one and only thing that happened today was Alliance Global Partners adding coverage of Vaccitech with a favourable buy recommendation.What’s truly eye-catching are the projections made, suggesting some pretty significant upside. The average one-year price target for Vaccitech is $12.24. Forecasts within this period have a bit of a spectrum, reaching from a low estimate of $7.07 to a high of $15.75. With that said, from today’s closing price that’s nearly 400% gain.

What’s The Big Deal?:

Alliance Global Partners giving the green light to cover Vaccitech is like a thumbs-up from a respected expert. It’s like a top-tier food critic saying, “This restaurant is a must-try.”

Think of it as Vaccitech stepping into the spotlight. It’s like a talented musician getting featured on a famous music blog—suddenly, more people start paying attention.

When a big player like Alliance Global Partners says, “Hey, this stock is a good buy,” it’s like a friend recommending a must-watch movie. You’re more likely to check it out based on that suggestion.

This kind of recommendation can also affect the stock price. It’s similar to when a popular influencer talks about a cool product—lots of people want to try it.

In a nutshell, this coverage is like a stamp of approval, making Vaccitech catch the attention of more potential investors and possibly giving the stock a boost. But it’s important to mention that just because a well established financial firm gives a price target, does not mean it’s accurate. In fact, tons of these projections are made daily with many being totally off the mark. Always do your own due diligence.

We will update you on VACC when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by spencerbdavis1 from Pixabay

 

 

 

Continue Reading

BioPharma

Advancing Medical Frontiers: Elutia Inc.’s(NASDAQ: ELUT) Strategic Vision in a $600 Million Market

Published

on

Elutia Inc (NASDAQ: ELUT) shares bolstered a whopping 33% today as the company recently shared that they’ve secured about $10.5 million in funding through a private investment round. If all the warrants are cashed in as part of this funding, the total could go up to $26.2 million.

Latest Changes:

Just last week, Aziyo Biologics changed its name to Elutia Inc. Following this change, Elutia made an announcement about selling its Orthobiologics business unit to Berkeley Biologics, a subsidiary of GNI Group Ltd. This move is set to bring in a substantial amount of cash, totalling up to $35 million for Elutia. This sum includes a notable upfront payment of $15 million, plus additional potential earnings of up to $20 million over five years. The deal is expected to be finalized in the fourth quarter of 2023.

This sale is a big step for Elutia, especially in the realm of drug-eluting biomatrix technology (DEB). Elutia is actively seeking approval from the FDA for their main product, CanGaroo RM. This product utilizes innovative biomatrix technology with antibiotics rifampin and minocycline (RM), providing long-term protection for cardiac pacemakers and defibrillators. This tackles a huge market estimated to be worth around 600 million. Elutia is aiming to introduce CanGaroo RM to the market in the first half of 2024.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Standard Of Care:

Medtronic (NYSE: MDT) stands as the exclusive provider of the antibiotic envelope within the current market. This envelope is crafted using synthetic mesh infused with antibiotics. Back in 2014, Medtronic acquired this technology, making a strategic investment of up to $200 million. Primarily intended for Cardiac Implantable Electronic Device (CIED) revision procedures, this product boasts estimated annual sales in the range of $250 to $300 million.

However, despite its market presence and revenue generation, the Medtronic antibiotic envelope has notable limitations. While it effectively combats infections, its synthetic composition renders it less effective in supporting wound healing. Moreover, it poses challenges in accommodating larger devices like Subcutaneous Implantable Defibrillators (SCID).

Drug-eluting biomatrix (DEB):

Drug-eluting biomatrix (DEB) involves a specialized approach to drug delivery using a biomatrix as a carrier or platform. In simple terms, it’s a technique where a biomaterial matrix, often a biocompatible polymer or similar substance, is used to release drugs in a controlled and targeted manner.

The biomatrix acts as a support structure that can hold and gradually release drugs or therapeutic agents at a specific site in the body, typically over an extended period. This is particularly useful in medical applications where a localized and sustained delivery of medication is necessary.

For instance, in the context of Elutia’s CanGaroo RM, a biomatrix incorporating antibiotics rifampin and minocycline is used to provide prolonged protection for cardiac pacemakers and defibrillators. The biomatrix slowly releases these antibiotics at the surgical site, preventing infections and promoting healing.

DEB technology is gaining traction because it enhances treatment efficiency by ensuring the drug is delivered directly to the target area, minimizing side effects, and optimizing therapeutic outcomes. It’s a promising approach in the field of medical advancements, especially in areas like cardiology, oncology, and orthopedics.

Post-mastectomy Breast Reconstruction:

On top of this, the company also has plans to develop an RM version of its SimpliDerm biomatrix tailored for breast reconstruction procedures. The rate of infections after this surgery is quite high, more than 10%, highlighting a big medical need in a market valued at over $500 million. Elutia is stepping up to address this issue by developing SimpliDerm® RM, which incorporates their unique DEB technology. The funds raised through the private investment round (PIPE) and the sale of the Orthobiologics business unit will not only boost Elutia’s efforts in advancing their drug-eluting biomatrix products for the cardiac pacemaker and defibrillator market, but also for post-mastectomy breast reconstruction.

What’s next:

As mentioned earlier, their biomatrix platform serves two major markets. CanGaroo RM, their upcoming product, is slated for a 1H of 2024 market release and is poised to be a pioneer in a $600 million market. Furthermore, their SimpliDerm RM product utilizes the same proprietary antibiotic-eluting technology found in CanGaroo RM, which serves a 1.6B market according to their presentation deck. They aim to secure an IDE by Q4 2024, and upon achieving these milestones, they plan to venture into neurostimulator markets, particularly in pain management, to further drive their growth.

We will update you on ELUT when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by sasint from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.